Skip to content

Patients › Foot

Úlcera do pé diabético

Updated Sep 2026
Illustration: foot

Esta página foi traduzida automaticamente e ainda não foi verificada por um médico. A versão em inglês é a versão oficial.

O que você está sentindo

Uma úlcera no pé diabético geralmente começa onde o sapato ou a meia causam atrito, frequentemente sob a planta da parte anterior do pé, em um dedo dobrado ou na lateral de uma protuberância óssea. Como o diabetes pode diminuir a sensibilidade nos pés, o primeiro sinal muitas vezes não é dor alguma. Pode ser uma bolha, uma rachadura entre os dedos, uma calosidade que escurece ou líquido na meia. Quando há dor, ela costuma estar localizada abaixo da úlcera; piora ao ficar em pé ou caminhar, e melhora quando você está sem carregar peso.

Vários fatores contribuem para o surgimento dessa condição. O dano nervoso pode fazer os dedos do pé se curvarem para baixo, como garras, e tensionar o tendão na parte de trás do tornozelo, desviando mais pressão para a frente do pé. A pele seca e rachada, devido à diminuição da sudorese, permite a entrada de bactérias. O estreitamento dos vasos sanguíneos abaixo do joelho reduz o fluxo sanguíneo para a ferida, dificultando sua cicatrização. Esses problemas são mais comuns em pessoas com diabetes há mais de uma década ou cujo nível de glicose no sangue é difícil de controlar.

A rotina diária sofre alterações sutis. Você pode perceber que passa a verificar a meia em busca de líquido todas as manhãs, ou opta por sapatos planos e espaçosos, pois qualquer calçado apertado irrita a área lesionada. Passear com o cachorro, ficar de pé perto do fogão ou ir às compras passam a exigir planejamento. Algumas pessoas notam inchaço, calor e vermelhidão no pé, que pode mudar de forma gradual. Caso ocorra infecção, podem surgir febre, tremores e maior dificuldade para controlar a glicose. Uma infecção profunda, por vezes, é o primeiro sinal de que alguém tem diabetes.

Se as articulações do meio do pé se deteriorarem, surge a chamada artropatia de Charcot: o pé fica vermelho, quente e inchado, podendo parecer infectado mesmo sem haver infecção real. Em até 50% dos casos, há dor; portanto, um pé sem dor, porém quente e inchado, também merece avaliação.

O que realmente está acontecendo

Uma úlcera no pé não é apenas um ponto dolorido. É o resultado final de diversas alterações graduais causadas pelo diabetes nos pés; compreendê-las ajuda a explicar por que a úlcera surge exatamente onde aparece.

A primeira alteração ocorre nos nervos. Com o tempo, o alto nível de glicose no sangue danifica os nervos responsáveis por transmitir as sensações dos pés ao cérebro. Imagine a fiação elétrica de uma casa: se o alarme estiver desconectado, você nunca o ouvirá tocar. Quando os nervos dos pés deixam de enviar sinais, você não sente a presença de uma pedra dentro do sapato, a formação de uma bolha ou o atrito de um calo. Essa perda de sensibilidade é chamada de perda da sensação protetora e é a razão mais comum para o surgimento dessas úlceras. Os nervos que controlam a sudorese também podem ser afetados, fazendo com que a pele resseque e rachure, facilitando a entrada de bactérias.

A segunda alteração diz respeito à forma e à mecânica do pé. Os pequenos músculos internos do pé enfraquecem, enquanto os músculos mais fortes na parte externa continuam a puxar. O resultado é que os dedos se curvam para baixo, como garras, e o tendão na parte de trás do tornozelo fica mais tenso. Isso desloca o peso do corpo para a parte anterior do pé, fazendo com que o mesmo ponto sofra pressão constante ao ficar em pé. A pressão sob o pé em pé (parado) pode chegar a 400 kPa; sem o sinal de alerta da dor, essa pressão nunca diminui, levando, por fim, à ruptura da pele.

A terceira alteração envolve a circulação sanguínea e as defesas do organismo. O diabetes estreita os vasos sanguíneos de tamanho médio abaixo do joelho, reduzindo o fluxo sanguíneo até a ferida. O sangue transporta o oxigênio e os elementos necessários para a cicatrização; portanto, com má circulação, o processo de cura fica mais lento ou até para. O alto nível de glicose também enfraquece o sistema imunológico, podendo atenuar os sinais habituais de infecção, como vermelhidão, calor e pus. É por isso que uma úlcera infectada pode parecer “tranquila” na superfície, enquanto a infecção se espalha por baixo.

Nenhuma dessas alterações pode ser totalmente revertida após ocorrer. O que se pode fazer é aliviar a pressão sobre a úlcera, melhorar a circulação quando possível, tratar a infecção e proteger o restante do pé de sofrer o mesmo destino.

O que podemos fazer a respeito

O primeiro passo é retirar a pressão sobre a úlcera para que ela possa fechar. Isso é chamado de “offloading”, ou seja, distribuir o peso do corpo por uma área maior do pé. As opções incluem sapatos especiais para cicatrização, palmilhas personalizadas ou gesso de contato total – um gesso bem ajustado que protege o pé durante a caminhada. O gesso é trocado a cada 2 a 4 semanas, até que a vermelhidão e o inchaço desapareçam e a temperatura do pé fique igual à do outro pé. Uma órtese de marcha é outra alternativa, mais fácil de retirar; porém, se a forma do pé estiver muito alterada, pode ser difícil usá-la. Os curativos mantêm a ferida úmida, absorvem o fluido e protegem contra infecções. Além disso, ensinamos como fazer a inspeção diária dos pés, cuidados seguros com unhas e calosidades, e como escolher calçados que não causem atrito. Após a cicatrização da úlcera, sapatos terapêuticos com palmilhas acolchoadas protegem os pés. O acompanhamento por uma equipe que pode incluir seu médico de família, educador em diabetes, podólogo e especialista vascular é fundamental: programas de cuidados com os pés como esse, aliados à educação do paciente, podem reduzir as taxas de amputação de membros inferiores em até 45% a 60%. Algumas feridas também respondem bem a tratamentos complementares, como a terapia por ondas de choque associada ao tratamento padrão; isso resultou no fechamento completo da ferida em 53,33% dos casos, contra 33,33% apenas com o tratamento padrão, com tempo de cicatrização de 60,8 dias em vez de 82,2 dias.

Caso a infecção tenha atingido o osso – condição conhecida como osteomielite – ou se houver formação de abscesso, a cirurgia passa a fazer parte do plano terapêutico. Geralmente, isso começa com a limpeza do tecido infectado, chamada de desbridamento, e o uso de antibióticos adequados ao tipo de bactéria encontrada. Às vezes, é preciso aparar parte do osso que pressiona a ferida, alongar um tendão rígido na parte de trás do tornozelo ou endireitar um dedo do pé encurvado. Para feridas graves, pode-se utilizar um sistema de alongamento cutâneo ou terapia de pressão negativa, que emprega sucção suave para auxiliar no fechamento da ferida. Quando o pé torna-se instável ou não pode ser estabilizado por órteses, a cirurgia pode realinhar e fundir as articulações para criar um pé estável e apto à marcha. Em alguns casos, é necessária a amputação de parte do pé; nesses casos, discutimos detalhadamente essa opção com você.

O que esperar

Uma úlcera no pé diabético pode cicatrizar, mas raramente acontece de forma rápida ou espontânea. A cicatrização depende de cinco fatores: glicemia controlada, eliminação da pressão sobre a ferida, bom fluxo sanguíneo para o pé, ausência de infecção e nutrição adequada. Se qualquer um desses fatores faltar, a úlcera tende a permanecer inalterada ou a reaparecer, em vez de fechar.

Com tratamento adequado, o processo costuma levar semanas ou meses, não apenas dias. A ferida é examinada e limpa a cada troca de gesso ou curativo, e radiografias são feitas a cada 4 a 6 semanas para monitorar os ossos. Esses prazos dão uma ideia do ritmo do processo, mesmo com cuidados intensivos.

É importante ser franco sobre o que acontece quando a úlcera é deixada sem tratamento: a infecção pode atingir os ossos, e as úlceras no pé diabético são responsáveis por cerca de 85% das amputações de membros inferiores em pessoas com diabetes. Caso seja necessária a remoção de parte do pé, o prognóstico varia. Após um tipo específico de amputação do meio do pé, 94% dos pacientes desenvolveram complicações na ferida e apenas 44% conseguiram caminhar com prótese. Após amputação abaixo do joelho, um terço dos pacientes não sobrevive nos dois primeiros anos, e cerca de 30% dos amputados perdem a outra perna em até 3 anos. São esses dados que motivam a equipe a priorizar a redução da pressão, a manutenção da circulação e o controle da infecção antes que a situação piore.

Mesmo quando a úlcera fecha, o trabalho ainda não termina. O mesmo local pode voltar a se lesionar; por isso, o uso de calçados terapêuticos com palmilhas acolchoadas e exames regulares do pé tornam-se parte da rotina. Em resumo: a ferida fecha com cuidados contínuos, mas será preciso proteger o pé por toda a vida para evitar novas lesões.

Quando procurar ajuda médica

Consulte seu médico de família se notar qualquer ruptura na pele do pé que não cicatrize em poucos dias, uma bolha, rachadura ou calo que pareça mais escuro ou esteja exsudando líquido, ou uma área que continua sendo friccionada no mesmo local. Solicite uma avaliação especializada se você não sentir absolutamente nada na área afetada, se a ferida for mais profunda que a pele, ou se for possível ver osso ou tendão nela. Procure o pronto-socorro se tiver febre, calafrios ou tremores, se a vermelhidão ou inchaço estiverem se espalhando pelo pé ou perna, se o pé estiver quente, vermelho e inchado sem nenhuma lesão aparente, ou se seu nível de açúcar no sangue de repente ficar difícil de controlar. Esses sinais podem indicar uma infecção profunda ou um abscesso, e exigem avaliação no mesmo dia, em vez de uma consulta com o médico de família.


Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

Epidemiology and Impact

  • Diabetic foot ulceration affects approximately 12% of patients with diabetes [1].
  • Diabetic foot ulcers are responsible for approximately 85% of lower extremity amputations in patients with diabetes mellitus [1].
  • Diabetic foot ulceration is the most common medical complication for which patients with diabetes seek treatment [1].
  • More than 80,000 diabetes-related amputations of the lower extremity are performed in the United States each year [22].
  • Approximately 40% of non-trauma related amputations in British hospitals are for complications of diabetes [2].
  • Approximately 30% of amputees undergo amputation of the contralateral limb within 3 years [22].
  • The 5-year mortality rate after amputation of a leg is approximately 66% [22].
  • Multidisciplinary foot care programs, along with comprehensive patient education, can reduce lower extremity amputation rates by as much as 45% to 60% [22].

Risk Factors and Pathophysiology

  • Factors associated with the inability of a diabetic foot ulcer to heal include persistently uncontrolled hyperglycemia, inability to unload the affected area effectively, diminished circulation, infection, and poor nutrition [1].
  • Problems with the diabetic foot are more common in patients who have been diagnosed as diabetic for more than a decade or who have poor glycaemic control [2].
  • Atherosclerosis in the diabetic foot affects mainly the medium-sized vessels below the knee [2].
  • Motor neuropathy leads to claw toes and high arches, which predispose to plantar ulceration [2].
  • Neuropathic joint disease (Charcot joints) occurs in less than 1% of diabetic patients [2].
  • The midtarsal joints are the most commonly affected joints in diabetic neuropathic joint disease, followed by the metatarsophalangeal and ankle joints [2].
  • Uncontrolled diabetes reduces immunity, and in combination with peripheral neuropathy and ischaemia, increases the risk of infection after minor trauma [2].
  • Loss of bone density in diabetes may be severe enough to result in insufficiency fractures around the ankle or in the metatarsals [2].
  • Sensory neuropathy is the most prevalent nerve dysfunction in diabetes, affecting as many as 70% of patients [7].
  • The critical triad of sensory neuropathy, trauma, and foot deformity was present in 63% of patients with lower extremity ulcers in one study [7].
  • Pain is associated with 25% to 33% of diabetic neuropathies [7].
  • Autonomic neuropathy causes sweat gland dysfunction, allowing the skin to dry out and crack, which allows the ingress of microbes [7].
  • Standing foot pressure can be as high as 400 kPa, necessitating fine regulation of blood vessels to ensure adequate oxygenation of tissues [7].

Microbiology

  • Diabetic foot infections are usually polymicrobial [1].
  • The most common pathogens in diabetic foot infections are aerobic gram-positive cocci, especially Staphylococcus aureus [1].
  • Gram-negative rods may be present in patients with chronic wounds or those recently treated with antibiotics [1].
  • Obligate anaerobic pathogens may cause infection in patients with foot ischemia or gangrene [1].
  • Deep cultures and bacterial biopsy are sometimes necessary to make a diagnosis of diabetic foot infection [1].

Evaluation and Diagnosis

  • A comprehensive evaluation of the diabetic foot should include assessment of tobacco use, prior treatments, medical comorbidities, and Achilles tendon tightness [1].
  • More than 60% of diabetic ulcers have diminished blood flow secondary to peripheral vascular disease [1].
  • An ankle-brachial index (ABI) of at least 0.45 and toe pressures greater than 40 mm Hg are necessary to heal an ulcer in the diabetic foot [1].
  • Transcutaneous oxygen measurement greater than 30 mm Hg indicates that blood flow is adequate for healing [1].
  • The Wagner ulcer classification system and the Brodsky depth-ischemia classification are commonly used for ulcer classification [1].
  • Key features of the physical examination for ulcer evaluation include depth of ulcer, presence of infection, nonviable tissue (gangrene), and pressure at the location of the ulcer [1].
  • Weight-bearing AP, lateral, and oblique radiographs of the foot and ankle are obtained for imaging evaluation [1].
  • Nuclear studies using technetium Tc-99m, gallium Ga-67, or indium In-111 may help differentiate between soft-tissue infection and osteomyelitis, Charcot arthropathy, or a combination of both [1].
  • MRI may not distinguish between Charcot arthropathy and infection with high specificity [1].
  • MRI can detect osteomyelitis quite early, well before radiographic abnormalities are visible [20].
  • The sensitivity of MRI for osteomyelitis approaches 100%, but the reported specificity is less [20].
  • In neuropathic patients, the specificity of MR signal abnormalities is reduced [20].
  • Normal MRI marrow signal confidently excludes osteomyelitis [20].
  • Osteomyelitis is present in 67% of ulcers that can be probed to bone [1].

Treatment Principles

  • Sharp débridement of necrotic tissue down to a clean tissue base often results in healing [1].
  • Wound dressings should provide a moist environment, absorb exudates, act as a barrier, off-load pressure, and occasionally provide antibiosis [1].
  • Total contact casting (TCC) is the benchmark for off-loading plantar ulcerations [1].
  • Patients with grade 3 or higher ulcers should undergo incision and drainage and antibiotic therapy, with wound improvement before TCC application [1].
  • TCC casts should be changed every 2 to 4 weeks until erythema and edema have resolved and the temperature of the affected limb has decreased and becomes similar to that of the contralateral limb [1].
  • Radiographs should be repeated every 4 to 6 weeks during TCC treatment, or more often if an acute change occurs [1].
  • A prefabricated pneumatic walking brace can be used as an alternative to TCC to reduce forefoot and midfoot plantar pressure [1].
  • Severe foot deformity makes using a pneumatic walking brace difficult, and patient compliance may be suboptimal [1].
  • Drainage of deep infections is often necessary to prevent tissue necrosis, rid the area of infection, and achieve wound healing without tension [1].
  • Ostectomy or realignment arthrodesis may be needed to remove the internal pressure caused by bony prominences [1].
  • Achilles tendon lengthening can help reduce plantar forefoot pressure [1].
  • Before antibiotic treatment is begun for osteomyelitis, specimens for culture should be obtained by biopsy, ulcer curettage, or aspiration, rather than by wound swab [1].
  • Dry gangrene of the toe can be left to demarcate before amputation [2].
  • Wet gangrene and infection may call for immediate amputation [2].
  • Arthrodesis for neuropathic joint disease has a very poor union rate [2].
  • 'Containment' of neuropathic joint disease in a weight-relieving orthosis may be the best option [2].
  • No proven method exists to reverse peripheral neuropathy associated with diabetes [7].
  • Medications from the gabapentin lineage, antidepressant medications, and topical anesthetics have been shown to relieve neuropathic pain to varied degrees [7].

Anatomy & Pathophysiology

Epidemiology and Risk

  • Diabetic foot ulcers affect approximately 12% of patients with diabetes [1].
  • A diabetic patient has a lifetime risk of developing a diabetic foot ulcer of 15%, with an annual incidence of 2% [10].
  • In 2010, there were 73,000 nontraumatic lower-limb amputations performed in adults aged 20 years and older with a diagnosis of diabetes [10].
  • Up to 25% of the annual expenditures on diabetic care are due directly to foot ulcers and their complications, including infection and amputation [10].
  • Diabetics who have previously had a foot ulcer or infection, or have undergone a partial or whole foot amputation, are at the greatest risk for developing a foot ulcer or foot infection [23].
  • Risk factors for those who have never had a foot ulcer or infection include peripheral neuropathy, peripheral vascular disease, and bony deformity [23].
  • Diabetic foot ulcers are most likely to occur secondary to external shearing forces, most commonly footwear, to skin overlying bony prominences [23].

Neuropathy

  • Diabetic neuropathy manifests in the somatic and/or autonomic parts of the peripheral nervous system [7].
  • Of all patients with diabetes mellitus, 10% have some form of sensory, motor, or autonomic dysfunction at the time of diagnosis [7].
  • Neuropathy develops in 50% of patients with diabetes within 25 years of diagnosis [7].
  • Sensory neuropathy is the most prevalent nerve dysfunction seen in patients with diabetes, affecting as many as 70% [7].
  • The critical triad of sensory neuropathy, trauma, and foot deformity was present in 63% of patients with lower extremity ulcers [7].
  • Sensory disturbances show a length-related pattern with stocking and glove distribution due to a “dying-back” distal axonopathy [7].
  • Protective sensation is indicated by the ability to perceive a 5.07 (10 g) Semmes-Weinstein monofilament applied perpendicular to the skin [7].
  • Loss of protective sensation (inability to perceive the 5.07 Semmes-Weinstein monofilament) is the most common cause of plantar foot ulcers [4, 5].
  • Loss of protective sensation is associated with a 30% risk of development of an ulcer [4, 5].
  • Motor neuropathy leads to the development of claw toes from intrinsic muscle weakness and equinus contracture of the Achilles tendon [7].
  • Claw toes occur because of the dysfunction of intrinsic muscles that cause hyperextension of the metatarsophalangeal joints and flexion of the proximal and distal interphalangeal joints [7].
  • Achilles tendon contracture displaces excessive pressure to the front of the foot, resulting in increased risk of ulceration [7].
  • Autonomic neuropathy occurs when the autonomic system cannot control the blood vessel tone and the sweat (eccrine and apocrine) glands in the foot [7].
  • Sweat gland dysfunction allows the skin to dry out and crack, thus allowing the ingress of microbes [7].
  • Standing foot pressure can be as high as 400 kPa, which necessitates fine regulation of the blood vessels to ensure adequate oxygenation of tissues and avoid local anoxia [7].
  • Studies have estimated that as many as 65% of people with type 1 or 2 diabetes have evidence of peripheral neuropathy [21].
  • The presence of peripheral neuropathy is the most predictive factor for the development of diabetic foot ulcers [21].
  • Neuropathy is an independent predictor of ulcers [21].
  • The length of time a patient has had diabetes and the level of metabolic control are the main predictors for the development, progression, and extent of neuropathy [21].
  • Weak intrinsic muscles become overpowered by stronger extrinsic muscles, leading to development of hammer toes, claw toes, and distal migration of the fat pad [21].
  • Muscle contractures of the gastrosoleus complex increase the force load transmitted to the forefoot [21].
  • The loss of protective sensation blunts the patient’s awareness of something being wrong and delays the request for care because of the absence of pain [21].

Vascular Pathophysiology

  • Peripheral vascular disease is present in 60% to 70% of patients who have had diabetes for more than 10 years [4, 5].
  • Atherosclerosis affects mainly the medium-sized vessels below the knee in patients with peripheral vascular disease [2].
  • Diabetic patients with peripheral arterial disease are nine times more likely to develop a foot ulcer [21].
  • Hyperglycemia can damage vascular endothelium, which is a precursor to atherosclerosis and leads to diminished extremity blood flow and limited healing potential [11].
  • An ABI of at least 0.45 and toe pressures greater than 40 mm Hg are necessary to heal an ulcer in the diabetic foot [1].
  • Transcutaneous oxygen values for the toes greater than 40 mm Hg have been found to be predictive of healing [4, 5].
  • Peripheral vascular disease can lead to falsely elevated ankle brachial indices [4, 5].

Metabolic and Tissue Changes

  • No single etiologic pathway has been confirmed as responsible for all diabetic neuropathy [7].
  • Metabolic factors (glycosylation of proteins, reduced availability of nerve growth factors, and immunologic factors) combined with a microvascular insufficiency likely result in the final common pathway of neuropathic changes [7].
  • With high levels of blood glucose, hemoglobin and proteins become glycosylated and form end products that precipitate in the walls of small peripheral vessels and nerve tissue [21].
  • Diabetic patients have glycation of the arterial vessel walls, thickening of the basement membranes, and reduced endothelial nitric oxide activity [21].
  • Metabolic causes of neuropathy include accumulation of sorbitol, enzyme deficiencies, and increased oxygen-free radical activity [21].
  • A histologic examination of the plantar skin of diabetic patients showed significantly thicker elastic septae and dermal layers compared to nondiabetic patients [21].
  • Ultrasound examinations of Achilles tendons have shown disorganized tendon fibers and calcification in 75% of diabetic patients without foot problems [21].
  • Peak midfoot joint pressures in diabetic cadaver feet during simulated walking were 46% higher in the first metatarsocuneiform, medial and middle naviculocuneiform, and the first intercuneiform joints compared to nondiabetic specimens [21].
  • Glucose covalently binds to lysine in proteins in a reversible process, changing the flexibility of tissues such as skin and making them less able to handle sheer stresses [11].
  • Elevated blood glucose levels over a long period lead to glycation of the body’s proteins, commonly measured by hemoglobin A1c [11].
  • Diabetes impairs the immune system because of alterations in the chemotaxis abilities of polymorphonuclear cells and cell wall abnormalities that make patients susceptible to secondary infections [21].

Charcot Arthropathy Pathophysiology

  • Up to 7.5% of patients with diabetes and neuropathy have Charcot arthropathy of the foot and ankle [14].
  • Of patients with Charcot arthropathy, 9% to 35% have bilateral involvement [14].
  • The neurotraumatic theory attributes bony destruction in Charcot foot to the loss of pain sensation and proprioception, combined with repetitive and mechanical trauma to the foot [14].
  • The neurovascular theory suggests that joint destruction in Charcot foot is secondary to an autonomic stimulated vascular reflex causing hyperemia and periarticular osteopenia with contributory trauma [14].
  • Trauma initiates a cytokine-mediated inflammatory process in patients with long-standing peripheral neuropathy, characterized by acute and chronic inflammation, osteoclastic bone resorption, and mechanical bony failure [41].
  • TNF-alpha and IL-1B lead to increased levels of NF-KB, which is responsible for increased osteoclast production and loss of bone [4, 5].
  • Motor imbalance between relatively weakened ankle dorsiflexors and overpowering plantar flexors leads to a relative dynamic ankle equinus loading during terminal stance phase of gait [41].
  • Loading of prepositioned dynamic equinus osteoporotic bone creates a bending moment akin to a “stress fracture” [41].
  • Autonomic peripheral neuropathy is expressed as loss of autonomic vascular tone, with resulting venous swelling [41].
  • Swollen tissues have less resistance to repetitive trauma, making tissue breakdown overlying bony deformity more likely [41].
  • The midtarsal joints are the most commonly affected in neuropathic joint disease, followed by the MTP and ankle joints [2].
  • Neuropathic joint disease occurs in less than 1% of diabetic patients [2].
  • Diabetes is the commonest cause of a neuropathic joint in Europe and North America [2].

Infection Pathophysiology

  • Diabetic infections are usually polymicrobial [1].
  • Infections in the diabetic foot or ankle are either isolated soft tissue infections (cellulitis or abscess) or osteomyelitis [19].
  • Hematogenous spread of infection into the foot or ankle is rare [19].

Classification

Ulcer Depth and Severity

  • The Wagner ulcer classification system is a commonly used tool for classifying diabetic foot ulcers [1].
  • The Brodsky depth-ischemia classification is a commonly used system for classifying diabetic foot ulcers [1].
  • The Meggitt-Wagner grading system is a validated tool used to risk stratify and determine treatment strategy for diabetic foot ulcers [8].
  • Wagner grade 0 patients are defined as having had a previous foot ulcer or infection or being "at risk" to develop an ulcer or infection [8].
  • Wagner grade I is defined as a superficial ulcer [8].
  • Wagner grade II is defined as a deep wound without abscess or bony involvement [8].
  • Wagner grade III ulcers are defined by the presence of an abscess or osteomyelitis [8].
  • Depth grade 0 ulcers are managed with an extra-depth shoe and pressure relief insoles [4].
  • Depth grade 1 ulcers are characterized by no bony involvement and superficial depth [4].
  • Depth grade 2 ulcers are characterized by deep ulceration with soft tissue exposure [4].
  • Depth grade 3 ulcers are characterized by extensive ulceration with osteomyelitis, abscess, or exposed bone [4].

Ischemia and Vascular Status

  • The Brodsky classification includes an ischemia-based grading system [1].
  • Ischemia grade A is defined as normal vascularity [4].
  • Ischemia grade B is defined as ischemia without gangrene [4].
  • Ischemia grade C is defined as partial forefoot gangrene [4].
  • Ischemia grade D is defined as complete foot gangrene [4].

Charcot Arthropathy

  • The Eichenholtz classification is the classic system for classifying Charcot arthropathy [14].
  • The Brodsky anatomic-based classification system categorizes Charcot foot into three types [14].
  • Brodsky Type 1 Charcot arthropathy involves the midfoot and accounts for approximately 60% of cases [14].
  • Brodsky Type 2 Charcot arthropathy involves the hindfoot and accounts for 30% to 35% of cases [14].
  • Brodsky Type 3 Charcot arthropathy involves the ankle or calcaneal tuberosity and accounts for the remaining 5% to 10% of cases [14].
  • Eichenholtz stage 0 is characterized by the acute inflammatory phase with a swollen, erythematous, warm, and hyperemic foot [14].
  • Eichenholtz stages 1 to 4 are characterized by soft tissue stabilization, subsiding swelling, and improving skin color [14].
  • Eichenholtz stage 4 is characterized by consolidation where foot stability may increase via arthrodesis or fibrous union [14].

Clinical Presentation

Epidemiology and Risk

  • Foot problems are the most common cause for hospitalization in diabetic patients, accounting for 20% or more of all inpatient days [11].
  • More than half of all nontraumatic amputations are performed on diabetics [11].
  • About 40% of non-trauma related amputations in British hospitals are for complications of diabetes [2].
  • Risk factors for patients who have never had a foot ulcer include peripheral neuropathy, peripheral vascular disease, and bony deformity [23].
  • Loss of protective sensation is the most common cause of plantar foot ulcers [4].
  • Studies estimate that as many as 65% of people with type 1 or 2 diabetes have evidence of peripheral neuropathy [21].

Pathophysiology and Clinical Features

  • Sensory neuropathy affects as many as 70% of patients with diabetes [7].
  • Pain is associated with 25% to 33% of neuropathies in diabetic patients [7].
  • Claw toes result from hyperextension of the metatarsophalangeal joints and flexion of the proximal and distal interphalangeal joints [7].
  • Autonomic neuropathy causes sweat gland dysfunction, allowing skin to dry out and crack, which allows the ingress of microbes [7].
  • Autonomic neuropathy blunts reactive hyperemia, which normally helps to clear infections [11].
  • Hyperglycemia impairs wound healing strength and damages vascular endothelium, leading to diminished extremity blood flow [11].
  • Elevated blood glucose levels lead to glycation of the body’s proteins, which changes the flexibility of tissues such as skin, making them less able to handle shear stresses [11].
  • Histologic examination shows significantly thicker elastic septae and dermal layers in diabetic plantar skin compared to nondiabetic tissue [21].
  • Ultrasound examinations show disorganized tendon fibers and calcification in 75% of diabetic patients without foot problems [21].
  • Diabetic patients have glycation of arterial vessel walls, thickening of basement membranes, and reduced endothelial nitric oxide activity [21].
  • Diabetic individuals are four times more likely to suffer a stroke than nondiabetic ones [21].
  • Diabetic individuals are twice as likely to develop peripheral arterial disease than nondiabetic ones [21].
  • Diabetes impairs the immune system due to alterations in the chemotaxis abilities of polymorphonuclear cells and cell wall abnormalities [21].

Physical Examination

  • A comprehensive evaluation should include assessment of tobacco use, prior treatments, medical comorbidities, and Achilles tendon tightness [1].
  • Physical examination of the lower extremity vascular system includes assessment of dorsalis pedis and tibialis pulses [1].
  • Examination of the skin should note the absence of hair on the feet and toes [1].
  • Key features of ulcer evaluation include depth of ulcer, presence of infection, nonviable tissue (gangrene), and pressure at the location of the ulcer [1].
  • Examination should begin with inspection of the shoe for internal and external wear patterns [11].
  • The leg and foot are inspected for overall appearance of skin, hair growth, perfusion, pulses, and color [11].
  • Bony prominences are recognized as areas of potential skin breakdown [11].
  • Common bony prominences include areas under the metatarsal heads, on the dorsum of the proximal interphalangeal joints, under the medial sesamoid, at the base of the fifth metatarsal, under the medial arch in the Charcot foot, and over the medial eminence of the hallux [11].
  • Ulcers should be measured for length, width, and depth, and their location documented [11].
  • Open wounds should be probed with a sterile Q-tip or other appropriate instrument to evaluate the extent of involvement of deeper structures such as tendons, joints, and bone [11].
  • A positive probe to bone test usually indicates the presence of osteomyelitis [11].
  • The "probe-to-bone" test is the most accurate test to identify a deep infection and the need for surgical intervention [42].
  • A positive probe-to-bone test virtually assures deep infection and the need for surgery [42].
  • A negative probe-to-bone test does not rule out deep infection [42].

Vascular Evaluation

  • An ankle-brachial index (ABI) of at least 0.45 is necessary to heal an ulcer in the diabetic foot [1].
  • Toe pressures greater than 40 mm Hg are necessary to heal an ulcer in the diabetic foot [1].
  • Patients with palpable pedal pulses and normal capillary filling have adequate blood supply and usually do not require further vascular evaluation [11].
  • An ischemic index of 0.45 or greater indicates a 90% chance that a foot ulcer will heal [11].

Imaging

  • Weight-bearing AP, lateral, and oblique radiographs of the foot and ankle are obtained for evaluation [1].
  • Nuclear studies using technetium Tc-99m, gallium Ga-67, or indium In-111 may help differentiate between soft-tissue infection and osteomyelitis, Charcot arthropathy, or a combination [1].
  • MRI can help differentiate conditions but may not distinguish between Charcot arthropathy and infection with high specificity [1].
  • Weight-bearing plain radiographs are used to characterize bony deformity and act as a baseline for diagnosing osteomyelitis [42].
  • Bony destruction with a break in the cortex is a late finding, making plain radiographs difficult to interpret [42].
  • Radionucleotide imaging has a high false-positive and false-negative rate [42].
  • MRI has a high false-positive and false-negative rate for diagnosing deep infection [42].
  • The diagnosis of deep infection and the need for surgery is primarily a clinical decision [42].

Classification

  • The Wagner ulcer classification system is commonly used for diabetic foot ulcers [1].
  • The Brodsky depth-ischemia classification is commonly used for diabetic foot ulcers [1].
  • The Meggitt-Wagner grading system is a validated tool used to risk stratify and determine treatment strategy [8].
  • Wagner grade 0 patients have either had a previous foot ulcer or infection or are “at risk” to develop an ulcer or infection [8].
  • Depth grade 0 ulcers are managed with extra-depth shoe and pressure relief insoles [4].
  • Depth grade 1 ulcers are superficial with no bony involvement [4].
  • Depth grade 2 ulcers are deep ulcers with soft tissue exposure [4].
  • Depth grade 3 ulcers are extensive ulcers with osteomyelitis or abscess and exposed bone [4].
  • Ischemia-based classification grade A indicates normal vascularity [4].
  • Ischemia-based classification grade B indicates ischemia without gangrene [4].
  • Ischemia-based classification grade C indicates partial forefoot gangrene [4].
  • Ischemia-based classification grade D indicates complete foot gangrene [4].

Microbiology and Infection

  • Diabetic patients with an abscess often present with clinical signs of sepsis characterized by fever, chills, hypotension, and hyperglycemia [42].
  • It is highly unusual for a diabetic foot abscess to develop in the absence of an ulcer, open wound, infected ingrown toenail, or skin crack between toes [42].
  • Hematogenous source of infection is rare in diabetic foot abscesses [42].

Charcot Arthropathy Presentation

  • Patients with Charcot arthropathy complain of swelling, warmth, redness, and deformity [4].
  • Pain is present in up to 50% of patients with Charcot arthropathy [4].
  • The midfoot is the most commonly affected site in Charcot arthropathy, followed by the ankle and then the hindfoot [4].
  • Early Charcot arthropathy is often confused with infection despite the lack of a substantially elevated white blood cell count or fever [14].
  • Normal blood glucose levels should discount infection in the differential diagnosis for Charcot arthropathy in patients with diabetes [14].
  • Stage 0 (acute) Charcot arthropathy presents with hyperemia of the foot with increased warmth and swelling [14].
  • Radiographs in Stage 0 Charcot arthropathy can show fracture or joint subluxation [14].
  • In Stages 1 to 4 of Charcot arthropathy, soft tissues stabilize, swelling subsides, and skin color improves [14].
  • The foot may develop deformity and instability in Stages 1 to 4 of Charcot arthropathy [14].
  • Type 1 Charcot arthropathy involves the midfoot and accounts for approximately 60% of cases [14].
  • Type 2 Charcot arthropathy involves the hindfoot and accounts for 30% to 35% of cases [14].
  • Type 3 Charcot arthropathy involves the ankle or calcaneal tuberosity and accounts for the remaining 5% to 10% of cases [14].

Investigations

History and Physical Examination

  • Physical examination of the lower extremity vascular system includes assessment of dorsalis pedis and tibialis pulses and examination of skin condition, noting the absence of hair on the feet and toes [1].
  • Regular examination for early signs of neuropathy should include the use of Semmes–Weinstein hairs for testing skin sensibility and a biothesiometer for testing vibration sense [2].
  • Peripheral vascular examination is enhanced by Doppler assessment [2].

Vascular Evaluation

  • When physical examination indicates further evaluation, the ankle-brachial index (ABI), Doppler ultrasonography with digital arterial pressures, transcutaneous toe oxygen measurement, and arteriography can be used [1].

Laboratory Evaluation

  • The accepted wound-healing levels are a serum albumin level of 3.0 g/dL and a total lymphocyte count greater than 1,500/mm3 [1].
  • Superficial wound culture does not identify the organism responsible for the infection and should not be performed [19, 37].
  • Culture of a deep surgical specimen or bone biopsy of exposed bone provides the most accurate result for identifying the causative organism [19, 37].

Imaging

  • Nuclear studies using technetium Tc-99m, gallium Ga-67, or indium In-111 may help differentiate between soft-tissue infection and osteomyelitis, Charcot arthropathy, or a combination of infection and Charcot arthropathy [1].
  • MRI can help in evaluation but may not distinguish between Charcot arthropathy and infection with high specificity [1].
  • MRI has a high false-positive rate in the diagnosis of osteomyelitis, particularly with concurrent Charcot arthropathy [19, 37].
  • Labeled WBC scan or dual-image technetium/indium (Tc/In) scan is more sensitive and specific for osteomyelitis than isolated Tc scan [19, 37].
  • MRI is a valuable imaging modality in the evaluation of patients with suspected bone or soft-tissue infection [20].
  • Osteomyelitis can be detected by MRI quite early, certainly well before radiographic abnormalities are visible [20].
  • The current workup of osteomyelitis in the diabetic foot often involves a combination of scintigraphy, MRI, laboratory data, and physical examination [20].
  • For the evaluation of surrounding soft-tissue infection, MRI is the modality of choice [20].
  • The addition of contrast-enhanced sequences to MRI is helpful in defining nonenhancing fluid collections/abscesses and devascularized or gangrenous tissue [20].
  • If abscess is suspected, needle aspiration or MRI is needed [19, 37].
  • Renal issues may preclude MRI with a contrast agent [19, 37].

Ulcer Classification

Treatment

Non-Operative Management

  • TCCs should be changed every 2 to 4 weeks until erythema and edema have resolved and the temperature of the affected limb has decreased and becomes similar to that of the contralateral limb [1].
  • Ulcers should be evaluated, and débridement should be performed at the time of cast changes [1].
  • Radiographs should be repeated every 4 to 6 weeks, or more often if an acute change occurs [1].
  • Pneumatic walking braces permit more frequent wound surveillance, allow several types of dressings, and are easy to apply [1].
  • The Medicare Therapeutic Shoe Bill covers one pair of custom-molded shoes with a total of three inserts or one pair of qualifying depth shoes with three inserts annually for qualified patients [1].
  • Qualified patients for the Therapeutic Shoe Bill include those being medically treated for diabetes with a history of neuropathy with callus, past ulcerations, foot deformity, past amputation, or poor circulation [1].
  • Medicare pays 80% of the cost for therapeutic shoes, with 20% charged to the approved patient or their supplemental insurance [1].
  • Grade I (superficial ulcer) or grade II (deep wound without abscess or bony involvement) ulcers can be treated as an outpatient with local débridement, empiric oral first-generation cephalosporin antibiotic therapy, and either a commercially available offloading device or total contact cast [8].
  • Once resolved, grade I and II ulcer patients are managed longitudinally with ongoing patient education, periodic monitoring, and therapeutic footwear [8].
  • The desired optimal clinical outcome for any patient with diabetic foot morbidity is an ulcer- and infection-free limb that can be managed longitudinally with commercially available depth-inlay therapeutic footwear and custom accommodative foot orthoses/insoles [9].
  • A proactive program combining foot-specific patient education, ongoing clinical monitoring, and accommodative footwear can decrease the incidence of diabetic foot ulceration, infection, and amputation [9].
  • Foot-specific patient education includes instruction on daily foot inspection, appropriate footwear, and instruction on nail and callus care [9].
  • The Medicare Therapeutic Shoe Bill of 1993 provides one pair of appropriate depth-inlay shoes and three insoles per year for Medicare-entitled individuals [9].
  • Patients with grade I and II wounds are managed as outpatients, where necrotic or infected tissue can be excised and calluses removed in an office or wound care clinic setting [9].
  • Longitudinal care of grade I and II wounds can be managed with simple dressings [9].
  • Patients with grade I and II wounds are allowed to bear weight in either a total contact cast or various commercially available “offloading” devices [9].
  • “Offloading” the wound is accomplished by distributing weight-bearing pressure over a large surface area with either a healing shoe, custom orthotic, commercially available fracture foot with pressure-dissipating insole, or a total contact cast [9].
  • Plastazote (closed cell—cross linked polyethylene) is often used to line the shoe and offload prominent areas [4].
  • Plastazote is lightweight, can absorb shock, and is able to be soft and compliant [4].
  • Acute Charcot arthropathy may be treated or resolved with TCC for 4 to 6 weeks [4].
  • Initial treatment of Charcot arthropathy is non-weight-bearing status with a TCC [4].
  • Neuropathic ulcers require total contact casts followed by custom-made shoes with total contact insoles to avoid recurrence [2].

Operative Management

  • Grade III ulcers are defined by the presence of an abscess or osteomyelitis and require a minimum of surgical débridement, culture-specific antibiotic therapy, and longitudinal care [8].
  • Grade 2 (deep ulcer with soft tissue exposure) requires operative débridement to healthy tissue followed by dressing changes/TCC [4].
  • Grade 3 (extensive ulcer with osteomyelitis or abscess and exposed bone) requires surgical débridement of bone/soft tissue followed by dressing changes/TCC [4].
  • Dorsal toe ulcers are best served with flexor tenotomies [4].
  • Treatment often requires Achilles lengthening to prevent recurrence of forefoot/midfoot ulceration [4].
  • Toe deformities often require joint resection or amputation [4].
  • Plantar hallux IP joint ulcers for which contact casting has failed should be treated with a Keller arthroplasty [4].
  • Débridement of infected tissue with use of negative-pressure dressings is recommended when infection prevents healing with conservative management [4].
  • Unstable/unbraceable deformities should be addressed with a tibiotalocalcaneal arthrodesis to afford a braceable/plantigrade foot while reducing risk of ulceration [4].
  • Use of an intramedullary rod for tibiotalocalcaneal arthrodesis affords internal stability and can be left indefinitely, in contrast to a multiplanar external fixator [4].
  • Even with radiographic evidence of nonunion after tibiotalocalcaneal arthrodesis, many patients can be pain-free [4].
  • ‘Containment’ of the problem in a weight-relieving orthosis may be the best option for neuropathic joint disease [2].

Amputation Considerations

  • Great toe (hallux) amputation results in increased pressures under the first metatarsal, lesser metatarsal heads, and remaining toes, increasing the risk of reulceration and further amputation [22].
  • Amputation of the second toe may result in hallux valgus deformity [22].
  • In general, forefoot stability is preserved if no more than two rays are resected [22].
  • Preserving the bases of the metatarsals allows the Lisfranc joint to remain stable [22].
  • Patients typically tolerate partial lateral foot amputations better than partial medial amputations [22].
  • First ray amputations can increase load to the adjacent rays [22].
  • Losing the anterior tibialis insertion during first ray amputation can weaken ankle dorsiflexion, resulting in pronation of the foot [22].
  • Fifth ray amputations are the most common [22].
  • Ray amputations are generally more durable and functional than transmetatarsal amputations (TMAs) [22].
  • The patient requires less energy for ambulation after a TMA than after a transtibial amputation [22].
  • A TMA leaves a patient with a distal weight-bearing residual limb [22].
  • Careful patient selection for TMA is required, including an assessment of muscle balance to determine the need for Achilles tendon lengthening and/or tendon transfer [22].
  • Lisfranc amputation is preferred over TMA when substantial soft-tissue loss of the forefoot is present [22].
  • Chopart amputation results in a shortened anatomic lever arm, reduced push-off, difficulty with stability, and possible equinovarus deformity [22].
  • Chopart amputation retains the tibiotalar joint and a functional residual limb [22].
  • Achilles tendon lengthening is usually necessary for Chopart amputation, as well as transfer of the extensors to the dorsal talus to prevent equinovarus deformity [22].
  • The primary advantage of a Syme amputation over more proximal amputations is its potential for achieving a full-load–bearing residual limb that is nearly normal in length and requires less energy expenditure during walking [22].
  • Candidates for a Syme amputation are patients with good potential for ambulation with a prosthesis following surgery, a viable heel pad, no infection at the heel pad level, and adequate vascularity [22].
  • The Syme amputation can be performed in two stages approximately 6 weeks apart; however, most surgeons use the single-stage technique because the results are essentially the same, but the cost and the risk of perioperative complications are lower with only one procedure [22].
  • Successful healing was reported in 84.5% of patients treated with single-stage Syme amputation [22].
  • Heel pad migration after a Syme amputation can be avoided by anchoring the heel pad to the distal tibia [22].

Complications

Epidemiology and Burden

  • Diabetic foot ulceration is responsible for approximately 85% of lower extremity amputations in patients with diabetes mellitus [1].
  • Diabetic foot morbidity leads to over 100,000 lower extremity amputations and early death yearly in the United States [12].
  • Foot problems are the most common cause for hospitalization in diabetics, accounting for 20% or more of all inpatient days in this population [11].
  • Medicare patients with a diabetic foot ulcer are seen by a health care provider an average of 14 times per year and have 1.5 hospitalizations each year at a reimbursed cost of $33,000 annually [10].
  • Patients with a lower extremity amputation have over $52,000 in reimbursed costs for Medicare services each year [10].
  • The total cost of diagnosed diabetes in the US was $327 billion in 2017, with $237 billion in direct medical costs and $90 billion in reduced productivity [10].
  • Average expenditures for medical costs are 2.3 times higher in patients with diabetes than those without [10].

Risk Factors for Non-Healing

  • Persistently uncontrolled hyperglycemia is a factor associated with the inability of a diabetic foot ulcer to heal [1].
  • Inability to unload the affected area effectively is a factor associated with the inability of a diabetic foot ulcer to heal [1].
  • Diminished circulation is a factor associated with the inability of a diabetic foot ulcer to heal [1].
  • Infection is a factor associated with the inability of a diabetic foot ulcer to heal [1].
  • Poor nutrition is a factor associated with the inability of a diabetic foot ulcer to heal [1].
  • Problems are more common in those who have been diagnosed as diabetic for more than a decade or who have poor glycaemic control [2].

Microbiology and Infection

  • Autonomic neuropathy causes dry skin and cracks in the dermis, which may become portals of entry for infection [11].
  • Reactive hyperemia, which normally helps to clear infections, is blunted by autonomic neuropathy [11].

Vascular Complications

  • Atherosclerosis affects mainly the medium-sized vessels below the knee in patients with diabetes [2].
  • If the ischemic index is 0.45 or greater, there is a 90% chance that a foot ulcer will heal [11].

Neuropathic Complications

  • Diabetic neuropathy develops in 50% of patients within 25 years of diagnosis [7].
  • Autonomic neuropathy occurs when the autonomic system cannot control the blood vessel tone and the sweat glands in the foot [7].
  • A minor provocative incident, such as a twisting injury or a fracture, leads to a painless progressive collapse of the joint in neuropathic joint disease [2].
  • X-rays show destruction of the joint in neuropathic joint disease [2].

Charcot Arthropathy

  • Charcot arthropathy is common in patients with diabetic neuropathy [4, 5].
  • The midfoot is most commonly affected in Charcot arthropathy, followed by the ankle and then the hindfoot [4, 5].
  • TNF-alpha and IL-1B lead to increased levels of NF-KB, which is responsible for increased osteoclast production and loss of bone in Charcot arthropathy [4, 5].
  • Fragmentation to consolidation in Charcot arthropathy may take 6 to 18 months [4, 5].
  • Arthrodesis has a very poor union rate in neuropathic joint disease [2].

Amputation Outcomes

  • The incidence of lower extremity amputation in the diabetic secondary to ischemic disease has been positively influenced by the proliferation of endovascular surgery [12].
  • Death rates for diabetic foot ischemia have not been radically improved, but it is likely that the proliferation of endovascular surgery has allowed affected patients to die without undergoing an amputation [12].
  • Amputation rates for diabetic foot infection have not drastically improved over the past decade [12].

Recovery

Factors Associated with Non-Healing

Vascular Thresholds for Healing

Nutritional Markers for Wound Healing

  • The accepted wound-healing level for serum albumin is 3.0 g/dL [1].
  • The accepted wound-healing level for total lymphocyte count is greater than 1,500/mm3 [1].

Off-Loading and Cast Management

  • TCC casts should be changed every 2 to 4 weeks until erythema and edema have resolved [1].
  • TCC casts should be changed every 2 to 4 weeks until the temperature of the affected limb has decreased and becomes similar to that of the contralateral limb [1].
  • Ulcers should be evaluated at the time of cast changes [1].
  • Débridement should be performed at the time of cast changes [1].
  • Radiographs should be repeated every 4 to 6 weeks during TCC treatment [1].
  • Radiographs should be repeated more often than every 4 to 6 weeks if an acute change occurs [1].

Alternative Off-Loading Devices

  • A pneumatic walking brace permits more frequent wound surveillance than TCC [1].
  • A pneumatic walking brace allows the use of several types of dressings [1].
  • A pneumatic walking brace is easy to apply [1].
  • Severe foot deformity makes using a pneumatic walking brace difficult [1].
  • Patient compliance with a pneumatic walking brace may be suboptimal [1].

Surgical Management for Healing

  • Drainage of deep infections is often necessary to prevent tissue necrosis [1].
  • Drainage of deep infections is often necessary to rid the area of infection [1].
  • Drainage of deep infections is often necessary to achieve wound healing without tension [1].

Osteomyelitis Considerations

  • Before antibiotic treatment is begun, specimens for culture should be obtained by biopsy, ulcer curettage, or aspiration rather than by wound swab [1].

References

[1] Aaos Comprehensive Orthopaedic Review 3. The Diabetic Foot and Ankle > II. Foot Ulceration.

[2] Apley And Solomon S Concise System Of Orthopaedics And Trauma. THE DIABETIC FOOT.

[4] Miller S Review Of Orthopaedics. SECTION 16 PATELLAR TRACKING IN TOTAL KNEE ARTHROPLASTY > SECTION 15 THE DIABETIC FOOT.

[5] Miller S Review Of Orthopaedics. SECTION 15 THE DIABETIC FOOT.

[7] Aaos Comprehensive Orthopaedic Review 3. The Diabetic Foot and Ankle > I. Diabetic Peripheral Neuropathy.

[8] Orthopaedic Knowledge Update 13 Ebook Without Multimedia. The Diabetic Foot > Diabetic Foot Ulcers and Foot Infection > Grading of Diabetic Foot Ulcers.

[9] Orthopaedic Knowledge Update 13 Ebook Without Multimedia. The Diabetic Foot > Diabetic Foot Ulcers and Foot Infection > Outpatient Treatment of Diabetic Foot Ulcers.

[10] Campbell S Operative Orthopaedics 4 Volume Set. COMBINED HAMMER TOE AND MALLET TOE DEFORMITY WITH ASSOCIATED DOUBLE CORNS > DIABETIC FOOT > EPIDEMIOLOGY.

[11] A Lange Medical Book Current Diagnosis Treatment In Orthopedics Fifth Edition. 8Foot and Ankle Surgery > DIABETIC FOOT.

[12] Orthopaedic Knowledge Update 13 Ebook Without Multimedia. The Diabetic Foot > Summary.

[14] Aaos Comprehensive Orthopaedic Review 3. The Diabetic Foot and Ankle > IV. Charcot Arthropathy of the Foot and Ankle.

[19] Miller S Review Of Orthopaedics. SECTION 16 PATELLAR TRACKING IN TOTAL KNEE ARTHROPLASTY > CLINICAL PROBLEMS > 3. Diabetic foot infections.

[20] Campbell S Operative Orthopaedics 4 Volume Set. OTHER DISORDERS OF FOOT AND ANKLE.

[21] Campbell S Operative Orthopaedics 4 Volume Set. COMBINED HAMMER TOE AND MALLET TOE DEFORMITY WITH ASSOCIATED DOUBLE CORNS > DIABETIC FOOT > BASIC SCIENCE.

[22] Aaos Comprehensive Orthopaedic Review 3. The Diabetic Foot and Ankle > III. Amputation.

[23] Orthopaedic Knowledge Update 13 Ebook Without Multimedia. The Diabetic Foot > Diabetic Foot Ulcers and Foot Infection > Risk Factors.

[37] Miller S Review Of Orthopaedics. CLINICAL PROBLEMS > 3. Diabetic foot infections.

[41] Orthopaedic Knowledge Update 13 Ebook Without Multimedia. The Diabetic Foot > Charcot Foot Arthropathy.

[42] Orthopaedic Knowledge Update 13 Ebook Without Multimedia. The Diabetic Foot > Diabetic Foot Ulcers and Foot Infection > Inpatient Management of Diabetic Foot Infection.

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International


Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees


Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.


Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.